Emerging Data Help Steer CDK4/6 Inhibitor Choice in HR+/HER2– Breast Cancer
Karen S. Anderson, MD, PhD, discusses emerging data and role for CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative breast cancer, along with the growing use of antibody-drug conjugates across the breast cancer spectrum and updates in triple-negative breast cancer.
Desai Discusses the Significance of a Supportive, Foundational Fellowship Experience
April 17th 2023Dr Desai discusses the aspects of his oncology fellowship experience that have had the greatest influence on his career growth, the role of mentorship throughout his fellowship and transition to a full-time faculty position, and his advice for current and future oncology fellows.
Colorectal Cancer: Prevalence, Workup, and Molecular Subtypes
Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.